Market Place
Sourcing Support
FDA & CEL-SCI Agree on PD-L1 Biomarker for Head & Neck Cancer Study
07 Nov 2024 //
BUSINESSWIRE
FDA Supports CEL-SCI’s Multikine® For PD-L1 Negative Cancer
22 Oct 2024 //
BUSINESSWIRE
CEL-SCI Selects Ergomed For Multikine® Registration Study
01 Oct 2024 //
BUSINESSWIRE
CEL-SCI`s Multikine Increased Survival In Head & Neck Cancer
16 Sep 2024 //
BUSINESSWIRE
CEL-SCI To Present Multikine® Data At ESMO 2024 Congress
10 Sep 2024 //
BUSINESSWIRE
UK MHRA Grants CEL-SCI Pediatric Waiver for Multikine®
04 Sep 2024 //
BUSINESSWIRE
CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results
15 Aug 2024 //
BUSINESSWIRE
CEL-SCI Announces Closing of $10.8 Million Offering
29 Jul 2024 //
BUSINESSWIRE
CEL-SCI`s Phase 3 Analysis Shows Balanced Population For Head & Neck Cancer
26 Jul 2024 //
BUSINESSWIRE
CEL-SCI Announces Pricing of $10.8 Million Offering
26 Jul 2024 //
BUSINESSWIRE
CEL-SCI Appoints Robert Watson as Chairperson of the Board
08 Jul 2024 //
BUSINESSWIRE
CEL-SCI Presents Data of Multikine For Head & Neck Cancer
18 Jun 2024 //
BUSINESSWIRE
Dr. Selvaggi, Oncology Expert, Joins CEL-SCI As Clinical Advisor
06 Jun 2024 //
BUSINESSWIRE
CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results
16 May 2024 //
BUSINESSWIRE
CEL-SCI: FDA Approval for Multikine Study in Head & Neck Cancer
08 May 2024 //
BUSINESSWIRE
CEL-SCI Appoints Mario Gobbo to Its Board of Directors
23 Apr 2024 //
BUSINESSWIRE
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Rheumatoid Arthritis
19 Mar 2024 //
BUSINESSWIRE
CEL-SCI Corporation Issues Letter to Shareholders
06 Mar 2024 //
BUSINESSWIRE
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
15 Feb 2024 //
BUSINESSWIRE
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
13 Feb 2024 //
BUSINESSWIRE
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
09 Feb 2024 //
BUSINESSWIRE
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility
06 Feb 2024 //
BUSINESSWIRE
EMA Grants CEL-SCI a Waiver of Strict Pediatric Requirements
31 Jan 2024 //
BUSINESSWIRE
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical Developments
22 Dec 2023 //
BUSINESSWIRE
CEL-SCI Releases Detailing Phase 3 & its Plans to Seek Regulatory Approvals
24 Oct 2023 //
BUSINESSWIRE
Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI’s Population
23 Oct 2023 //
BUSINESSWIRE
CEL-SCI Readies Multikine Manufacturing Facility for Commercial Scale Production
19 Oct 2023 //
BUSINESSWIRE
CEL-SCI Files Request With UK’s MHRA Regarding Path to Approval for Multikine
05 Oct 2023 //
BUSINESSWIRE
CEL-SCI Submits Advice Filing to EMA for Multikine in the Treatment of Cancer
26 Sep 2023 //
BUSINESSWIRE
CEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results
11 Aug 2023 //
BUSINESSWIRE
CEL-SCI Announces Closing of Public Offering
20 Jul 2023 //
BUSINESSWIRE
CEL-SCI Announces Proposed Public Offering of Common Stock
17 Jul 2023 //
BUSINESSWIRE
CEL-SCI Concludes Positive Meeting With U.S. FDA Concerning Multikine’s Approval
14 Jul 2023 //
BUSINESSWIRE
CEL-SCI Corporation Reports First Quarter Fiscal 2023 Financial Results
15 Feb 2023 //
BUSINESSWIRE
CEL-SCI’S Phase 3 Data Presented at ESMO 2022
12 Sep 2022 //
BUSINESSWIRE
CEL-SCI Presents Phase 3 Multikine Head & Neck Cancer Data at ASCO
07 Jun 2022 //
BUSINESSWIRE
CEL-SCI Announces Acceptance of Abstracts to ASCO 2022
22 Apr 2022 //
BUSINESSWIRE
CEL-SCI Corporation Reports First Quarter Fiscal 2022 Financial Results
14 Feb 2022 //
BUSINESSWIRE
CEL-SCI Reports Fiscal 2021 Financial Results, Clinical & Corporate Developments
22 Dec 2021 //
BUSINESSWIRE
CEL-SCI Corporation Completes Commercial-Scale Buildout Multikine MFG Facility
22 Oct 2021 //
BUSINESSWIRE
CEL-SCI Corporation Reports Third Quarter Fiscal 2021 Financial Results
16 Aug 2021 //
BUSINESSWIRE
CEL-SCI Corporation Issues Letter to Shareholders
08 Jul 2021 //
BUSINESSWIRE
Cel-Sci CEO tries to spin cancer trial failure into an FDA win
08 Jul 2021 //
FIERCEBIOTECH
The failure of a cancer drug study leaves Cel-Sci on the brink of collapse
07 Jul 2021 //
STAT
Discussion of Results of CEL-SCI’s Phase 3 Trial Is Now Available
02 Jul 2021 //
BUSINESSWIRE
Cel-Sci cancer phase 3 misses primary endpoint, sinking stock
29 Jun 2021 //
FIERCEBIOTECH
CEL-SCI’s Multikine® Immunotherapy Produces Significant Year Survival Benefit
28 Jun 2021 //
BUSINESSWIRE
CEL-SCI Announces the Closing of $31.7 Million Bought Deal Offering
11 Jun 2021 //
BUSINESSWIRE
CEL-SCI Announces the Closing of $31.7 Million Bought Deal Offering
11 Jun 2021 //
BUSINESSWIRE
CEL-SCI Announces the Closing of $31.7 Million Bought Deal Offering
11 Jun 2021 //
BUSINESSWIRE
CEL-SCI Increases Previously Announced Bought Deal to $31.7 Million
09 Jun 2021 //
BUSINESSWIRE
CEL-SCI Announces Bought Deal Offering
08 Jun 2021 //
BUSINESSWIRE
CEL-SCI Increases Previously Announced Bought Deal to $31.7 Million
08 Jun 2021 //
BUSINESSWIRE
CEL-SCI Announces Update on Phase 3 Cancer Trial Results
07 Dec 2020 //
BUSINESSWIRE
CEL-SCI Corporation Issues Letter to Shareholders
15 Sep 2020 //
BUSINESSNEWS WIRE
CEL-SCI Announces Early Results with COVID 19 LEAPS Vaccine/Treatment
23 Jul 2020 //
BUSINESSWIRE
CEL-SCI Corporation Receives $10 Million Through Warrant Exercises
30 Jun 2020 //
BUSINESSWIRE
CEL-SCI’s Pivotal Phase 3 Study Has Reached the Required Number of Events
04 May 2020 //
BUSINESSWIRE
CEL-SCI Announces the Closing of Its $7.7 Million Bought Deal
26 Mar 2020 //
BUSINESSWIRE
CEL-SCI Increases Previously Announced Bought Deal to $7.7 Million
24 Mar 2020 //
BUSINESSWIRE
